A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Completed · Phase 3 · NCT04294667
Conditions: Systemic Lupus Erythematosus
At a glance
- Research payments reported, 2025
- $159,300
- U.S. investigators named
- 19
- Sites paid
- 19
- Planned or actual enrollment
- 321
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- DZP (drug), Placebo (other)
- Dates
- Started 2020-08-12; completion 2024-06-04
- Results posted
- Yes
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
From ClinicalTrials.gov, last updated 2025-05-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $159,300 in research payments for this study in 2025 (20 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jose E. Rubio Mosquera, M.D Rheumatology · Birmingham, AL
- Jeffrey B. Loomer, MD Rheumatology · Tucson, AZ
- Sheetal R. Desai, MD Rheumatology · Orange, CA
- Gerald Y. Ho, M.D. Rheumatology · La Palma, CA
- Kenneth C. Kalunian, MD Rheumatology · San Diego, CA
- Smitha Reddy, M.D. Rheumatology · Poway, CA
- Daniel J. Wallace, MD Rheumatology · Beverly Hills, CA
- Michael R. Bubb, MD Rheumatology · Gainesville, FL
- Vipul M. Joshi, MD Specialist · Brandon, FL
- Guillermo J. Valenzuela, MD Specialist · Plantation, FL
- Sung S. Lim, M.D., M.P.H. Rheumatology · Atlanta, GA
- Wambui Machua, M.D. Rheumatology · Atlanta, GA
- Housam A. Sarakbi, MD Rheumatology · Louisville, KY
- Enrique A. Mendez, M.D. Rheumatology · Lake Charles, LA
- Mary P. Howell, MD Internal Medicine · Hagerstown, MD
- Andreea Coca, MD Rheumatology · Pittsburgh, PA
- Alan Kivitz, MD Rheumatology · Duncansville, PA
- Nancy J. Olsen, MD Rheumatology · Hershey, PA
- Dhiman Basu, MD Rheumatology · Colleyville, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Pittsburgh Physicians $26,349
- Iris Research and Development LLC $22,976
- Advanced Medical Research $13,728
- University of Alabama Hospital, AL $13,209
- Precision Comprehensive Clinical Research Solutions, LLC $9,750
- Emory University Hospital, GA $9,225
- Uci Health-Orange, CA $8,839
- Ronald Reagan UCLA Medical Center, CA $8,836
- Advanced Clinical Research Center LLC $7,166
- University of Florida $7,145
- Weitzner, Yonker, Kaine MD. $6,382
- Wayne State University $5,701
- Vipul Joshi MD PA $5,550
- Pennsylvania State University College of Medicine $5,000
- Accurate Clinical Research Inc $4,188
- Klein & Associates MD PA $2,700
- Wallace Rheumatic Study Center LLC $2,000
- Augusta University Research Institute, Inc. $423
- Arizona Arthritis and Rheumatology Research $134
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.